New CRISPR/Cas9 license agreement to advance disease model development

Ricoh Company, Ltd has announced a non-exclusive licensing agreement with ERS Genomics Ltd for access to foundational CRISPR/Cas9 genome editing technology patents in the USA and Japan.

CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise modification of targeted genome sequences. It plays a crucial role in drug discovery and is utilised in various research fields.

In 2022, Ricoh acquired Elixirgen Scientific, Inc, which specialises in rapid and efficient differentiation of human iPS cells and mRNA design, production, and management. Combining these technologies with CRISPR/Cas9, Ricoh aims to enhance the prediction of drug mechanisms for patients with diverse genetic backgrounds and to improve mRNA design speed and efficiency. This integration allows for the creation of reliable disease models, including those for rare diseases, potentially shortening drug development timelines and increasing success rates.

Ricoh is expanding the application of Elixirgen Scientific's technology by utilising its expertise in digital and artificial intelligence technologies. This initiative aims to accelerate personalised medicine, drug discovery research, and regenerative medicine. Ricoh is committed to advancing drug development research through the diverse solutions offered by Elixirgen Scientific.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, is the exclusive representative of ERS Genomics in Japan.

More information online